Biogen Inc (NASDAQ: BIIB) has reported earnings for its second fiscal quarter (ending June 30) of $4.01 versus $4.09 for the same period a year ago. For the latest four quarters through June 30, E.P.S. were $7.97 compared to $18.46 a year ago.
Recent Price Action
Biogen Inc (NASDAQ: BIIB) stock closed at $210.70 on 8/1/24 after a modest decline of -1.2%. Moreover, unusually high trading volume at 178% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -6.8% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, BIIB is expected to continue to be a major Value Builder.
Biogen has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Biogen has a neutral Appreciation Score of 58 but a poor Power Rating of 24, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment